Gadqua 列車市場規模、佔有率及成長分析（按應用程式、最終用戶和地區）- 2025 年至 2032 年產業預測

2023 年，電子設備季銨鹽-2 市場規模價值 19 億美元，預計將從 2024 年的 20 億美元成長到 2032 年的 29.7 億美元，預測期內（2025-2032 年）的複合年成長率為 5.1%。

預計 MRI顯影劑市場將出現顯著成長，這得益於癌症、神經系統疾病和心血管疾病等慢性疾病的發病率不斷上升，這些疾病需要精確的成像才能進行有效的診斷和治療計劃。最新的進展包括四聚體钆四極體，這是一種高效的分子钆基顯影劑(mGBCA)，以其優異的物理化學特性而聞名，例如高弛豫率和穩定性以及最小的蛋白質結合。該藥物反映了現有 mGBCA 的藥物動力學特徵，表現出快速分佈和腎臟排泄。此外，老年人口的成長和對非侵入性診斷技術的日益傾向預計將在未來幾年進一步推動市場成長，凸顯 MRI顯影劑在現代醫療保健中的重要作用。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究

加德庫阿火車市場規模（按應用）及複合年成長率（2025 年至 2032 年）

• 市場概覽
• 篩檢
• 診斷

加德庫阿火車市場規模（依最終用戶分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 醫院
• 診斷中心
• 專科診所
• 其他

加德庫阿火車市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Bayer AG（Germany）
• GE Healthcare（United States）
• Guerbet Group（France）
• Bracco Imaging SpA（Italy）
• Lantheus Medical Imaging, Inc.（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Spago Nanomedical AB（Sweden）
• Trivitron Healthcare（India）
• Jodas Expoim Pvt. Ltd.（India）
• CMR Naviscan Corporation（United States）
• Subhra Pharma Pvt. Ltd.（India）
• Macrocyclics, Inc.（United States）
• iMax Diagnostic Imaging Limited（China）
• Beijing Beilu Pharmaceutical Co., Ltd.（China）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.（China）
• Yantai Dongcheng Pharmaceutical Group Co., Ltd.（China）
• Sanochemia Pharmazeutika AG（Austria）
• Medtronic plc（Ireland）

結論和建議

Gadoquatrane Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2.0 billion in 2024 to USD 2.97 billion by 2032, growing at a CAGR of 5.1% during the forecast period (2025-2032).

The MRI contrast media agents market is poised for substantial growth, fueled by the rising incidence of chronic diseases including cancer, neurological disorders, and cardiovascular issues that necessitate precise imaging for effective diagnosis and treatment planning. Among the latest advancements is tetrameric gadoquatrane, a highly effective molecular gadolinium-based contrast agent (mGBCA) known for its superior physicochemical properties, such as high relaxivity and stability, along with minimal protein binding. This agent mirrors the pharmacokinetic profiles of existing mGBCAs, demonstrating rapid distribution and kidney excretion. In addition, the expanding elderly population and the increasing inclination towards non-invasive diagnostic techniques are anticipated to further catalyze market growth over the coming years, underscoring the critical role of MRI contrast agents in contemporary healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Gadoquatrane market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Gadoquatrane Market Segments Analysis

Global Gadoquatrane Market is segmented by Application, End User and region. Based on Application, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Gadoquatrane Market

The Gadoquatrane market is being driven by the escalating demand for MRI contrast media agents, fueled by several key factors. Notably, the rising prevalence of chronic illnesses, an aging population, and the preference for non-invasive diagnostic methods are significantly contributing to this trend. Additionally, advancements in technology and increased healthcare expenditures are further enhancing market growth. Research has shown the effectiveness of gadolinium-based contrast agents (GBCAs) in contrast-enhanced magnetic resonance imaging (CE-MRI), with over 620 million treatments administered globally and around 30 million CE-MRI procedures conducted annually. GBCAs, particularly those featuring paramagnetic gadolinium, optimize MRI signal enhancement, making Gadoquatrane an exceptional candidate for clinical development and increasing its demand in the market.

Restraints in the Gadoquatrane Market

Several factors contribute to the constraints on demand and subsequent price reduction for MRI contrast media agents in the Gadoquatrane market. Notably, the high costs associated with these agents lead both patients and healthcare providers to consider alternative diagnostic methods, especially in light of the increasing healthcare expenditure. Additionally, advancements in non-contrast MRI techniques are enhancing their accuracy and efficacy, thereby diminishing the reliance on contrast agents. Safety concerns, including rare adverse effects such as allergic reactions and nephrogenic systemic fibrosis (NSF), further discourage use. Furthermore, the healthcare industry's shift towards value-based care promotes high-quality yet cost-effective solutions, encouraging a preference for other imaging modalities like ultrasonography or CT scans, which can further limit the demand for MRI contrast agents.

Market Trends of the Gadoquatrane Market

The Gadoquatrane market is witnessing a significant shift towards safer imaging alternatives due to rising concerns over the side effects associated with gadolinium-based contrast agents, particularly in patients with renal impairments. As healthcare professionals and patients demand improved safety profiles, the focus is increasingly turning to gadolinium-free contrast agents, including innovative iron oxide nanoparticles and manganese-based compounds. This trend not only reflects a growing awareness of patient safety but also opens new avenues for research and development within the pharmaceutical industry. Consequently, the Gadoquatrane market is poised for growth as it aligns with these evolving patient care standards and technological advancements.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Gadoquatrane Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnosis

Global Gadoquatrane Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital
• Diagnostic Centres
• Specialty Clinics
• Others

Global Gadoquatrane Market Size & CAGR (2025-2032)

• North America (Application, End User)
  • US
  • Canada
• Europe (Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spago Nanomedical AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trivitron Healthcare (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jodas Expoim Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CMR Naviscan Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Subhra Pharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrocyclics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• iMax Diagnostic Imaging Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanochemia Pharmazeutika AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations